Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 2,706 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all

Conditions: Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Wound Complication, Wound Heal, Complications Wound, Surgical Wound Infection, Surgical Site Infection, Breast Cancer, Mastectomy; Lymphedema
Interventions: Impact Advanced Recovery; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure, Systolic
Interventions: Autologous cell therapy, Sham; Biological · Other
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Interventions: CART-19; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: carcinoembryonic antigen peptide 1, hepatitis B antigen peptide; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease
Interventions: ANPD001, Custom Device; Biological · Device
Lead sponsor: Aspen Neuroscience; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 6 more

Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Procedure
Lead sponsor: Aldagen; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Dietary Intervention, Medical Chart Review, Questionnaire Administration; Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Graft Versus Host Disease, Lymphoma
Interventions: aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: B Cell Leukemias, B Cell Lymphomas
Interventions: Cohort 1, Cohorts 2, Cohort 3, Cohort 3A; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 1 Year to 29 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Autologous T-regulatory lymphocytes, Interleukin-2; Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurogenic Bladder
Interventions: Autologous neobladder construct; Device
Lead sponsor: Tengion; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Crohn's Disease
Interventions: Autologous Stem Cell Transplantation; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Knee
Interventions: APS; Biological
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Elkhart, Indiana

Conditions: Multiple Myeloma
Interventions: filgrastim, bortezomib, melphalan, Stem Cell Infusion; Biological · Drug · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shoulder Pain, Shoulder Impingement Syndrome, Rotator Cuff Impingement Syndrome, Rotator Cuff Tendinitis, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Spinal Cord Injuries
Interventions: Autologous micro-fragmented adipose tissue, Lipogems system; Biological · Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions: DKK1; Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Renal Cell Carcinoma
Interventions: AGS-003; Drug
Lead sponsor: Argos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: Group 1 (preoperative radiation hypofractionated), Group 2 (preoperative radiation conventionally fractionated); Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: ADP-A2M4 in combination with pembrolizumab.; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more

Conditions: Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leukotriene, Montelukast, Stem Cell Transplant
Interventions: Singulair (Montelukast Sodium); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 6 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions: Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone; Procedure · Drug · Radiation + 1 more
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
Interventions: Autologous Natural Killer / Natural Killer T Cell Immunotherapy; Biological
Lead sponsor: Envita Medical Center, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction

CardiAMP™ Cell Therapy for Heart Failure Trial

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer

Phase 1/2a Study of ANPD001 in Parkinson Disease

ALD-301 for Critical Limb Ischemia, Randomized Trial

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

CD22 Redirected Autologous T Cells for ALL

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

Crohn's Disease Stem Cell Transplantation

Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

A Rollover Protocol for Subjects Previously Treated With AGS-003

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Montelukast to Treat Bronchiolitis Obliterans

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer